Oncology Search
Oncology Oncology
Content not found!
Editor's Recommendations
Most Read Articles
New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer
Natalia Reoutova, 26 Jan 2021

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.